SAFETY AND EFFICACY OF TOFACITINIB, AN ORAL JANUS KINASE INHIBITOR, UP TO 36 MONTHS IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: DATA FROM THE THIRD INTERIM ANALYSIS OF OPAL BALANCE, AN OPEN-LABEL, LONG-TERM EXTENSION STUDY

被引：8
|
作者：
Nash, P. [1 ]
Coates, L. C. [2 ]
Kivitz, A. J. [3 ]
Mease, P. J. [4 ,5 ]
Gladman, D. D. [6 ]
Covarrubias-Cobos, A. [7 ]
Fleishaker, D. [8 ]
Wang, C. [8 ]
Kudlacz, E. [8 ]
Menon, S. [8 ]
Fallon, L. [9 ]
Hendrikx, T. [10 ]
Kanik, K. S. [8 ]
机构：
[1] Univ Queensland, Brisbane, Qld, Australia
[2] Univ Oxford, Oxford, England
[3] Altoona Ctr Clin Res, Duncansville, PA USA
[4] Swedish Med Ctr, Seattle, WA USA
[5] Univ Washington, Seattle, WA 98195 USA
[6] Univ Toronto, Toronto Western Hosp, Toronto, ON, Canada
[7] Unidad Reumatol Las Amer SCP, Merida, Mexico
[8] Pfizer Inc, Groton, CT 06340 USA
[9] Pfizer Canada, Montreal, PQ, Canada
[10] Pfizer Inc, Collegeville, PA USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2018年 / 77卷
关键词：
D O I：
10.1136/annrheumdis-2018-eular.3115
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
SAT0293
引用
收藏
页码：1010 / 1011
页数：2
相关论文
共 50 条
  • [41] Safety and efficacy of tofacitinib for the treatment of patients with juvenile idiopathic arthritis: preliminary results of an open-label, long-term extension study
    Brunner, Hermine I.
    Akikusa, Jonathan D.
    Al-Abadi, Eslam
    Bohnsack, John F.
    Boteanu, Alina Lucica
    Chedeville, Gaelle
    Cuttica, Ruben
    De La Pena, Wendy
    Jung, Lawrence
    Kasapcopur, Ozgur
    Kobusinska, Katarzyna
    Schulert, Grant S.
    Neiva, Claudia
    Rivas-Chacon, Rafael
    Rizo Rodriguez, Juan Cruz
    Vazquez-Del Mercado, Monica
    Wagner-Weiner, Linda
    Weiss, Jennifer E.
    Wouters, Carine
    Posner, Holly
    Wouters, Ann
    Chang, Cheng
    White, Claire
    Kanik, Keith
    Liu, Shixue
    Martini, Alberto
    Lovell, Daniel J.
    Ruperto, Nicolino
    ANNALS OF THE RHEUMATIC DISEASES, 2024, 83 (11) : 1561 - 1571
  • [42] Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study
    Papp, Kim A.
    Krueger, James G.
    Feldman, Steven R.
    Langley, Richard G.
    Thaci, Diamant
    Torii, Hideshi
    Tyring, Stephen
    Wolk, Robert
    Gardner, Annie
    Mebus, Charles
    Tan, Huaming
    Luo, Yingchun
    Gupta, Pankaj
    Mallbris, Lotus
    Tatulych, Svitlana
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : 841 - 850
  • [43] Long-term efficacy and safety with zonisamide: Interim analysis of an open-label study
    Wroe, S
    Brodie, MJ
    EPILEPSIA, 2005, 46 : 118 - 118
  • [44] Long-term Safety of Filgotinib in Patients with Psoriatic Arthritis, Week 52 Safety Data from a Phase 2 Open-Label Extension Study
    Coates, Laura
    Mease, Philip
    Gladman, Dafna
    Van den Bosch, Filip
    Rychlewska-Hanczewska, Anna
    Tasset, Chantal
    Meuleners, Luc
    Trivedi, Mona
    Gao, Jingjing
    Besuyen, Robin
    Helliwell, Philip
    ARTHRITIS & RHEUMATOLOGY, 2019, 71
  • [45] Long-Term Safety of Filgotinib in Patients with Psoriatic Arthritis, Week 52 Safety Data from a Phase 2 Open-Label Extension Study
    Gladman, Dafna
    Coates, Laura
    Mease, Philip
    van den Bosch, Filip
    Rychlewska-Hanczewska, Anna
    Tasset, Chantal
    Meuleners, Luc
    Trivedi, Mona
    Guo, Ying
    Besuyen, Robin
    Helliwell, Philip
    JOURNAL OF RHEUMATOLOGY, 2020, 47 (07) : 1066 - 1067
  • [46] ABP 501 Long-Term Safety/Efficacy: Interim Results from an Open-Label Extension Study
    Cohen, Stanley
    Pablos, Jose L.
    Zhang, Nan
    Rizzo, Warren
    Muller, Gerhard
    Padmanaban, Devi
    Kivitz, Alan
    Matsumoto, Alan K.
    Kaur, Primal
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [47] LONG-TERM EFFICACY OF THE ORAL SELECTIVE JANUS KINASE 1 INHIBITOR FILGOTINIB IN PSORIATIC ARTHRITIS: WEEK 52 RESPONSE PATTERNS IN INDIVIDUAL PATIENTS FROM AN OPEN-LABEL EXTENSION (OLE) STUDY (EQUATOR2)
    Gladman, D. D.
    Coates, L. C.
    Van den Bosch, F.
    Helliwell, P.
    Tasset, C.
    Meuleners, L.
    Gilles, L.
    Gheyle, L.
    Trivedi, M.
    Alani, M.
    Besuyen, R.
    Mease, P. J.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 759 - 759
  • [48] TOFACITINIB, AN ORAL JANUS KINASE INHIBITOR: LONG-TERM EXTENSION STUDY OUTCOMES IN AN AUSTRALIAN RHEUMATOID ARTHRITIS POPULATION
    Hall, S.
    Nash, P.
    Rischmueller, M.
    Bossingham, D.
    Cook, N.
    Witcombe, D.
    Kwok, K.
    Thirunavukkarasu, K.
    INTERNAL MEDICINE JOURNAL, 2014, 44 : 26 - 26
  • [49] TOFACITINIB, AN ORAL JAK INHIBITOR, IN THE TREATMENT OF ULCERATIVE COLITIS: OPEN-LABEL, LONG-TERM EXTENSION STUDY
    Bloom, Stuart
    Lichtenstein, Gary R.
    Loftus, Edward V.
    Lawendy, Nervin
    Friedman, Gary S.
    Zhang, Haiying
    Wang, Wenjin
    Thorpe, Andrew J.
    Nduaka, Chudy I.
    Su, Chinyu
    GUT, 2018, 67 : A62 - A63
  • [50] Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study
    Jürgen Wollenhaupt
    Eun-Bong Lee
    Jeffrey R. Curtis
    Joel Silverfield
    Ketti Terry
    Koshika Soma
    Chris Mojcik
    Ryan DeMasi
    Sander Strengholt
    Kenneth Kwok
    Irina Lazariciu
    Lisy Wang
    Stanley Cohen
    Arthritis Research & Therapy, 21
12345